Search

Your search keyword '"Julie Vasseur"' showing total 2 results
Start Over Author "Julie Vasseur" Topic 0302 clinical medicine
2 results on '"Julie Vasseur"'

1. Chronological occurrence of PI3KCA mutations in breast cancer liver metastases after repeat partial liver resection

Author

Giulia Hardoin, Julie Vasseur, Aldrick Ruiz, Marc-Antoine Allard, Jean-François Morère, Jocelyne Hamelin, Mylène Sebagh, Nelly Bosselut, René Adam, Antoinette Lemoine, Raphaël Saffroy, Department of Surgery [Utrecht, Pays-Bas], University Medical Center [Utrecht], Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Pathologie [Villejuif], Hôpital Paul Brousse, Physiopathogenèse et Traitement des Maladies du Foie [Villejuif], Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'Oncogénétique [Villejuif], Université Paris-Sud - Paris 11 (UP11), Département de Cancérologie [Villejuif], The Netherlands Organization for Scientific Research (NOW). Grant number: 017.009.053., Physiopathogénèse et Traitement des Maladies du Foie, Hôpital Paul Brousse-Université Paris-Saclay, and Bodescot, Myriam

Subjects
0301 basic medicine, Cancer Research, Time Factors, medicine.medical_treatment, Metastases, medicine.disease_cause, Gastroenterology, 0302 clinical medicine, Circulating tumor cell, Surgical oncology, Recurrence, Prevalence, Medicine, Breast, Cancer, Aged, 80 and over, Mutation, Liver Neoplasms, Nuclear Proteins, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, Oncology, Liver, 030220 oncology & carcinogenesis, Biomarker (medicine), Female, France, Research Article, Adult, Reoperation, medicine.medical_specialty, Lineage (genetic), Evolution, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, lcsh:RC254-282, 03 medical and health sciences, Breast cancer, [SDV.CAN] Life Sciences [q-bio]/Cancer, Lineage, Internal medicine, Genetics, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Hepatectomy, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Aged, PI3KCA, business.industry, medicine.disease, 030104 developmental biology, business, Transcription Factors
Abstract

International audience; BACKGROUND:Liver metastases of breast cancer are frequent and can recur even after "complete/R0" resection in combination with systemic and hormonal treatments. The aim of this study was to analyze throughout repeat hepatectomies for liver metastases the evolution of PI3KCA gene mutational status.METHODS:All liver metastases nodules (n = 70) from 19 women who underwent at least 2 liver resections were reexamined. DNA extraction from archived tumoral tissue was performed and the major 'hot spot' mutations in the helical and catalytic domains of PI3KCA have been analyzed using Massarray platform (Agena Bioscience) based on allelic discrimination PCR amplification followed by sensitive mass spectrometry detection.RESULTS:The two major somatic hot spot PI3KCA mutations were found in 27 (38.6%) nodules corresponding to 8 of the 19 patients (42%). The frequency of women whose breast cancer liver metastases (BCLM) carries PI3KCA mutations increased from the first to the third hepatectomy. Tumors carrying PI3KCA mutations are significantly larger and more frequently observed when resections were R0 compared to patients with no PI3KCA mutation.CONCLUSION:PI3KCA mutations are frequently observed in BCLM and persist along with the recurrence. Their identification in circulating tumor cells should become a useful biomarker in the routine practice of breast cancer management to prevent tumor recurrence and overcome the problems of intra- and inter-tumoral heterogeneity of the current biomarkers.

Published
2019

2. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas

Author

Nicolas Girard, Alexis B. Cortot, Denis Moro-Sibilot, Antoinette Lemoine, Raphaël Saffroy, Sylvie Lantuejoul, Xavier Mignard, Isabelle Rouquette, Nathalie Rabbe, Anne-Marie Ruppert, Julie Vasseur, Marie Wislez, Julien Mazieres, Jacques Cadranel, Vincent Fallet, Françoise Thivolet-Béjui, Martine Antoine, Sorbonne Université (SU), Theranoscan [CHU Tenon] (GRC 4), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Theranoscan, Université Pierre et Marie Curie - Paris 6 (UPMC), Service d’Anatomie et cytologie pathologiques [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Paul Brousse, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Hospices Civils de Lyon (HCL), Hôpital Louis Pradel [CHU - HCL], CHU Grenoble, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Léon Bérard [Lyon], Site de Recherche Intégrée en Cancérologie (SIRIC-ONCOLille), Université de Lille, Sciences et Technologies-Université de Lille, Sciences Humaines et Sociales-Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER-Université Lille Nord de France (COMUE)-UNICANCER-Cancéropole Nord-Ouest-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe de recherche clinique Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules (GRC 4 - Theranoscan), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lille-UNICANCER-Université de Lille-UNICANCER-Cancéropole Nord-Ouest-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
0301 basic medicine, Oncology, Male, Lung Neoplasms, [SDV]Life Sciences [q-bio], MET Exon 14 Mutation, Cohort Studies, chemistry.chemical_compound, Exon, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Medicine, Copy-number variation, In Situ Hybridization, Fluorescence, Chromosome 7 (human), Aged, 80 and over, biology, medicine.diagnostic_test, Carcinoma, Giant Cell, Sarcoma, Exons, Middle Aged, Proto-Oncogene Proteins c-met, Prognosis, Immunohistochemistry, 3. Good health, 030220 oncology & carcinogenesis, MET, Female, Antibody, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, C-Met, Amplification, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, Humans, Aged, Lung sarcomatoid carcinoma, business.industry, Gene Amplification, 030104 developmental biology, chemistry, Mutation, biology.protein, Exon 14 mutations, business, Fluorescence in situ hybridization, Follow-Up Studies
Abstract

Introduction MNNG HOS transforming gene (MET) abnormalities such as amplification and exon 14 mutations may be responsive to targeted therapies. They are prevalent in lung sarcomatoid carcinomas (LSCs) and must be diagnosed as efficiently as possible. Hypothetically, c-MET overexpression by immunohistochemistry (IHC) may prove effective as a screening test for MET abnormalities. Methods Tissue samples were obtained from consecutive patients with a resected LSC in four oncologic centers. IHC was performed using the SP44 antibody (Ventana, Tucson, Arizona) and evaluated using the MetMab score and H-score. Fluorescence in situ hybridization was applied with the dual color probe set from Zytovision (Clinisciences, Nanterre, France). True MET amplification was diagnosed when MET gene copy number was 5 or greater and the ratio between MET gene copy number and chromosome 7 number was greater than 2. All MET exon 14 alterations including those affecting splice sites occurring within splice donor and acceptor sites were detected in the routine molecular testing on genetic platforms. Results A total of 81 LSCs were included. Fourteen (17%) exhibited positive IHC using the MetMab score and 15 (18.5%) using the H-score. MET amplification was detected in six tumors (8.5%) and MET exon 14 mutation in five (6%). A weak positive correlation between IHC and fluorescence in situ hybridization was found (r = 0.27, p = 0.0001). IHC sensitivity for MET amplification was 50%, with a specificity of 83%, positive predictive value of 21.4%, and negative predictive value of 94.7%. IHC sensitivity for MET exon 14 mutations was 20%, with a specificity of 83%, positive predictive value of 7%, and negative predictive value of 94%. Conclusion IHC is not a relevant screening tool for MET abnormalities in LSC.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results